Literature DB >> 21653673

Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.

B K Chakrabarti1, L M Walker, J F Guenaga, A Ghobbeh, P Poignard, D R Burton, R T Wyatt.   

Abstract

On the prereceptor-engaged HIV-1 envelope glycoprotein (Env) spike, epitope access by the membrane-proximal external region (MPER)-directed broadly neutralizing antibodies 2F5 and 4E10 remains unresolved. Data on binding to cell surface Env and entry data using primary isolates suggest inaccessibility of the 2F5 and 4E10 epitopes on the viral spike prior to receptor engagement, but trimer gel shift analysis and slow kinetics of shedding induced by 2F5 and 4E10 indicate otherwise. Therefore, it remains unclear if the epitopes themselves are formed in their antibody-bound state (or at least sampled) prior to receptor/coreceptor engagement or if receptor interactions both expose and form the MPER epitopes, presumably in the putative prefusion transitional intermediate. Here, we performed antibody-virus "washout experiments" using both lab-adapted and a panel of clade B primary isolates to analyze MPER accessibility. The neutralization activity of 2F5 and 4E10 against lab-adapted viruses and sensitive and moderately resistant viruses was largely unaffected by relatively rapid antibody-virus washing, suggesting direct interaction with the "static" spike. However, for more neutralization-resistant viruses, the 2F5 and 4E10 antibodies could neutralize only under the "no antibody-virus wash" conditions, implying that the MPER epitopes were not accessible prior to receptor engagement. Accessibility in the washout conditions could be precisely predicted by the relative resistance to neutralization in a standard neutralization format. These data are consistent with a model in which the local MPER antibody epitope conformations may be sampled on the native spike but are occluded to antibody by local steric or distal quaternary constraints adopted by highly resistant HIV-1 isolates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653673      PMCID: PMC3147955          DOI: 10.1128/JVI.00756-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

3.  Role of HIV membrane in neutralization by two broadly neutralizing antibodies.

Authors:  S Munir Alam; Marco Morelli; S Moses Dennison; Hua-Xin Liao; Ruijun Zhang; Shi-Mao Xia; Sophia Rits-Volloch; Li Sun; Stephen C Harrison; Barton F Haynes; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

4.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

5.  Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.

Authors:  Xiaoying Shen; S Moses Dennison; Pinghuang Liu; Feng Gao; Frederick Jaeger; David C Montefiori; Laurent Verkoczy; Barton F Haynes; S Munir Alam; Georgia D Tomaras
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

Review 6.  The HIV Env-mediated fusion reaction.

Authors:  Stephen A Gallo; Catherine M Finnegan; Mathias Viard; Yossef Raviv; Antony Dimitrov; Satinder S Rawat; Anu Puri; Stewart Durell; Robert Blumenthal
Journal:  Biochim Biophys Acta       Date:  2003-07-11

7.  Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.

Authors:  Q J Sattentau; S Zolla-Pazner; P Poignard
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

8.  Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

Authors:  Markus Koch; Marie Pancera; Peter D Kwong; Peter Kolchinsky; Christoph Grundner; Liping Wang; Wayne A Hendrickson; Joseph Sodroski; Richard Wyatt
Journal:  Virology       Date:  2003-09-01       Impact factor: 3.616

9.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

10.  MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1.

Authors:  Claudia R Ruprecht; Anders Krarup; Lucy Reynell; Axel M Mann; Oliver F Brandenberg; Livia Berlinger; Irene A Abela; Roland R Regoes; Huldrych F Günthard; Peter Rusert; Alexandra Trkola
Journal:  J Exp Med       Date:  2011-02-28       Impact factor: 14.307

View more
  60 in total

Review 1.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

2.  Role for the terminal clasp of HIV-1 gp41 glycoprotein in the initiation of membrane fusion.

Authors:  Chan-Sien Lay; Louise E Ludlow; David Stapleton; Anna K Bellamy-McIntyre; Paul A Ramsland; Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2011-10-05       Impact factor: 5.157

3.  Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle.

Authors:  Grant S Hansman; David W Taylor; Jason S McLellan; Thomas J Smith; Ivelin Georgiev; Jeremy R H Tame; Sam-Yong Park; Makoto Yamazaki; Fumio Gondaira; Motohiro Miki; Kazuhiko Katayama; Kazuyoshi Murata; Peter D Kwong
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

4.  Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.

Authors:  Malika Hale; Taylor Mesojednik; Guillermo S Romano Ibarra; Jaya Sahni; Alison Bernard; Karen Sommer; Andrew M Scharenberg; David J Rawlings; Thor A Wagner
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

5.  Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues.

Authors:  Anthony P West; Louise Scharf; Joshua Horwitz; Florian Klein; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

6.  The membrane proximal external regions of gp41 from HIV-1 strains HXB2 and JRFL have different sensitivities to alanine mutation.

Authors:  Hyun Ah Yi; Barbara Diaz-Rohrer; Priyanka Saminathan; Amy Jacobs
Journal:  Biochemistry       Date:  2015-02-19       Impact factor: 3.162

Review 7.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

8.  Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins.

Authors:  Shitao Zou; Shijian Zhang; Althea Gaffney; Haitao Ding; Maolin Lu; Jonathan R Grover; Mark Farrell; Hanh T Nguyen; Connie Zhao; Saumya Anang; Meiqing Zhao; Mohammadjavad Mohammadi; Scott C Blanchard; Cameron Abrams; Navid Madani; Walther Mothes; John C Kappes; Amos B Smith; Joseph Sodroski
Journal:  J Virol       Date:  2020-05-04       Impact factor: 5.103

Review 9.  Insights into vaccine development for acquired immune deficiency syndrome from crystal structures of human immunodeficiency virus-1 gp41 and equine infectious anemia virus gp45.

Authors:  Liangwei Duan; Jiansen Du; Xinqi Liu
Journal:  Protein Sci       Date:  2015-09-21       Impact factor: 6.725

Review 10.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.